Skip to main content

vismodegib

Generic: VISMODEGIB·Brand: ERIVEDGE, Erivedge

vismodegib: sourced relationships with 1 company · 5 clinical trials tracked.

vismodegib evidence translation

What we can confirm

5 tracked trials

What it means

Source-backed records connect vismodegib to CRIS; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could vismodegib → CRIS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 0 study sponsors

Related indications

Treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiationAdvanced Solid TumorsBreast CarcinomaCancerCervical CarcinomaColorectal CarcinomaEndometrial CarcinomaGlioma

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
CURIS INC (CRIS)
developer · Reported 2024-02-08 · Current development: unknownSource
Treatment of adults with metastatic basal cell carcinoma (BC…
Approved
Clinical Trial Registry Records (5)

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

NCT05651828Registry updated 2026-04-01·Early Phase 1
Recruiting

Primary endpoint: Time to Treatment Failure

InterventionalRandomizedopen34 targetStarted 2023-03Completion 2029-121 site · United StatesH. Lee Moffitt Cancer Center and Research Institute

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

NCT03297606Registry updated 2026-03-27·Phase 2
Recruiting

Primary endpoint: Objective response rate defined as the number of patients with complete response or partial response

Interventionalopen720 targetStarted 2018-03Completion 2027-0110 sites · CanadaCanadian Cancer Trials Group

A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

NCT02925234Registry updated 2024-01-24·Phase 2
Recruiting

Primary endpoint: Percentage of patients that are treated based on their molecular tumor profile

Interventionalopen1,550 targetStarted 2016-08Completion 2027-1236 sites · NetherlandsThe Netherlands Cancer Institute

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

NCT02523014Registry updated 2026-09-02·Phase 2
Recruiting

Primary endpoint: Progression free survival (PFS)

Interventionalopen124 targetStarted 2015-09Completion 2028-0150 sites · United StatesAlliance for Clinical Trials in Oncology

Molecular Analysis for Therapy Choice (MATCH)

NCT02465060Registry updated 2026-02-27·Phase 2
Active, not recruiting

Primary endpoint: Objective response rate (ORR)

Interventionalopen6,452 targetStarted 2015-08Completion 2026-1250 sites · United StatesNational Cancer Institute (NCI)

Frequently asked questions

Which companies have sourced relationships with vismodegib?

vismodegib has dated SEC/FDA relationship records for CURIS INC.

How many clinical trials involve vismodegib?

BioSniper tracks 5 clinical trials involving vismodegib.